Shares of Steris PLC (NYSE:STE) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $80.25.
A number of brokerages have weighed in on STE. KeyCorp restated a “buy” rating and issued a $103.00 price objective on shares of Steris in a report on Thursday, February 8th. Zacks Investment Research upgraded shares of Steris from a “hold” rating to a “buy” rating and set a $103.00 price objective on the stock in a report on Tuesday, January 23rd. Northcoast Research set a $102.00 price objective on shares of Steris and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Raymond James Financial restated a “market perform” rating and issued a $100.00 price objective on shares of Steris in a report on Wednesday, January 3rd.
Shares of Steris (STE) opened at $95.85 on Tuesday. The firm has a market cap of $8,077.54, a PE ratio of 33.63 and a beta of 1.17. The company has a quick ratio of 2.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.46. Steris has a fifty-two week low of $67.55 and a fifty-two week high of $96.34.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be paid a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.29%. The ex-dividend date is Tuesday, February 27th. This is an increase from Steris’s previous quarterly dividend of $0.21. Steris’s dividend payout ratio is currently 43.51%.
In other news, VP Karen L. Burton sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.59, for a total value of $128,385.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Cynthia L. Feldmann sold 3,218 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $91.35, for a total transaction of $293,964.30. Following the completion of the transaction, the director now owns 11,214 shares in the company, valued at approximately $1,024,398.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,415 shares of company stock worth $6,223,536. Insiders own 2.55% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Captrust Financial Advisors bought a new position in shares of Steris in the fourth quarter worth approximately $101,000. Meeder Asset Management Inc. lifted its stake in shares of Steris by 1,122.4% in the fourth quarter. Meeder Asset Management Inc. now owns 1,198 shares of the medical equipment provider’s stock worth $104,000 after buying an additional 1,100 shares in the last quarter. YorkBridge Wealth Partners LLC bought a new position in shares of Steris in the fourth quarter worth approximately $113,000. Zions Bancorporation bought a new position in shares of Steris in the third quarter worth approximately $178,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Steris in the fourth quarter worth approximately $241,000. Hedge funds and other institutional investors own 89.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Steris PLC (STE) Given Consensus Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/13/steris-plc-ste-given-consensus-rating-of-buy-by-analysts.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.